CTOs on the Move

ValenTx

www.valentx.com

 
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.valentx.com
  • 6901 East Fish Lake Road Suite 118
    Maple Grove, MN USA 55369
  • Phone: 763.222.1560

Executives

Name Title Contact Details

Funding

ValenTx raised $10.3M on 08/15/2018

Similar Companies

Scanlan Worldwide

Scanlan Worldwide is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SheerVision Inc

SheerVision Inc is a Rolling Hills Estates, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amicable Healthcare Inc

Amicable Healthcare Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pocono Medical Care Inc

Pocono Medical Care Inc is a Milford, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cvrx

CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.